Ahead Of Patent Loss, Takeda’s Actos Benefits From Avandia Drop Off
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Takeda Pharmaceutical's diabetes treatment Actos registered stronger-than-expected sales in the April-September period, benefiting from a price increase in the U.S. and the restricted use or market withdrawal of competitor Avandia